Skip to content

Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Suppositories.

Randomized Clinical Trial for Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Suppositories.

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03005353
Enrollment
100
Registered
2016-12-29
Start date
2018-03-01
Completion date
2020-01-31
Last updated
2020-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection, Fungal

Brief summary

Fungal infections have increased over the last two decades, largely because of the increasing size of the population at risk, including patients who are immunocompromised, broad-spectrum antibiotics and intravascular catheter users. Essential oils and other extracts of plants have evoked interest as sources of natural products. They have been shown to possess antibacterial, antifungal, antiviral, insecticidal and antioxidant properties. To the best of our knowledge, no study has examined the efficacy of cumin seed extract on relieving vulvovaginal candidiasis in vivo.

Interventions

DRUGCumin seed extract

patients will receive the drug in suppository form

patients will receive the drug in suppository form

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 49 Years
Healthy volunteers
No

Inclusion criteria

1. Women were 18-49 years old and were married; 2. They had not used antibiotics, immunosuppressive drugs, or vaginal drugs 14 days before the study; 3. They did not suffer from trichomonal vaginitis, bacterial vaginitis, or cervicitis based on direct smear; 4. Candidiasis culture was in agreement with clinical symptoms and patient's complaints.

Exclusion criteria

1. Pregnant and lactating women; 2. Those who had abnormal uterine bleeding; 3. Women with diabetes or autoimmune diseases; 4. Women refuse to participate in the study.

Design outcomes

Primary

MeasureTime frameDescription
The percentage of patients with complete cureone weekcure is defines as absence of symptoms

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026